A study examining the effectiveness of the recombinant zoster vaccine (RZV) over a 4-year period found that two doses of the vaccine provided strong protection against herpes zoster, or shingles, even in patients on corticosteroids. The overall vaccine effectiveness was 64% for one dose and 76% for two doses, with the effectiveness of full vaccination at 73% after 3 to 4 years. These findings support the recommendation for adults aged 50 years and older to receive two doses of the vaccine. However, the overall effectiveness of two RZV doses was lower than that found in previous clinical trials.
Source link
Two doses of recombinant zoster vaccine provide strong protection against shingles
